Arcellx/$ACLX
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Arcellx
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Ticker
$ACLX
Sector
Primary listing
Employees
163
Headquarters
Website
Arcellx Metrics
BasicAdvanced
$4.8B
-
-$3.43
0.28
-
Price and volume
Market cap
$4.8B
Beta
0.28
52-week high
$107.37
52-week low
$47.86
Average daily volume
519K
Financial strength
Current ratio
3.807
Quick ratio
3.746
Long term debt to equity
11.498
Total debt to equity
13.389
Interest coverage (TTM)
-1,611.97%
Profitability
EBITDA (TTM)
-208.075
Gross margin (TTM)
-202.30%
Net profit margin (TTM)
-329.93%
Operating margin (TTM)
-376.26%
Effective tax rate (TTM)
-0.94%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-19.80%
Return on equity (TTM)
-42.75%
Valuation
Price to revenue (TTM)
83.035
Price to book
12.17
Price to tangible book (TTM)
12.17
Price to free cash flow (TTM)
-38.389
Free cash flow yield (TTM)
-2.60%
Free cash flow per share (TTM)
-2.246
Growth
Revenue change (TTM)
-60.64%
Earnings per share change (TTM)
223.66%
3-year earnings per share growth (CAGR)
-19.10%
Bulls say / Bears say
The Phase 2 iMMagine-1 trial of anito-cel achieved a 97% overall response rate and 93.3% minimal residual disease negativity in relapsed/refractory multiple myeloma patients as of May 1, 2025, demonstrating potential best-in-class efficacy.
Arcellx finished Q2 2025 with $537.6 million in cash, cash equivalents, and marketable securities, ensuring funding into 2028 and reducing commercialization risk.
The FDA approved an investigational new drug application for ACLX-004, targeting acute myeloid leukemia through Arcellx’s ARC-SparX platform, signifying progress in its pipeline beyond multiple myeloma.
Collaboration revenue fell 72% year-over-year to $7.6 million in Q2 2025, missing analyst forecasts by 43.8%, highlighting the company’s dependence on one-time deal income.
Net loss expanded to $52.8 million in Q2 2025, more than double the $27.2 million loss in Q2 2024, as Arcellx increased spending to prepare for commercial launch planned in 2026.
General and administrative expenses increased 34.1% to $28.7 million in Q2 2025, resulting in higher cash burn as Arcellx ramps up for commercialization without corresponding revenue growth.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arcellx stock?
Arcellx (ACLX) has a market cap of $4.8B as of October 14, 2025.
What is the P/E ratio for Arcellx stock?
The price to earnings (P/E) ratio for Arcellx (ACLX) stock is 0 as of October 14, 2025.
Does Arcellx stock pay dividends?
No, Arcellx (ACLX) stock does not pay dividends to its shareholders as of October 14, 2025.
When is the next Arcellx dividend payment date?
Arcellx (ACLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Arcellx?
Arcellx (ACLX) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.